Sirona Biochem Corp - Asset Resilience Ratio
Sirona Biochem Corp (SBM) has an Asset Resilience Ratio of 0.02% as of January 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2019)
This chart shows how Sirona Biochem Corp's Asset Resilience Ratio has changed over time. Check Sirona Biochem Corp strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Sirona Biochem Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Sirona Biochem Corp market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$732.00 | 0.02% |
| Total Liquid Assets | CA$732.00 | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Sirona Biochem Corp maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sirona Biochem Corp Industry Peers by Asset Resilience Ratio
Compare Sirona Biochem Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Sirona Biochem Corp (2011–2019)
The table below shows the annual Asset Resilience Ratio data for Sirona Biochem Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-10-31 | 0.02% | CA$734.00 ≈ $530.96 |
CA$4.26 Million ≈ $3.08 Million |
-0.04pp |
| 2017-10-31 | 0.06% | CA$752.00 ≈ $543.99 |
CA$1.25 Million ≈ $904.98K |
-24.70pp |
| 2011-10-31 | 24.76% | CA$855.78K ≈ $619.06K |
CA$3.46 Million ≈ $2.50 Million |
-- |
About Sirona Biochem Corp
Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, engages in the development and sale of cosmetic and pharmaceutical active ingredients in Canada and France. The company's programs include cosmetic skin lightener and diabetes drug; and other projects comprise the development of an anti-aging/cell protection library, anti-wrinkle compound, and anti-viral program. The company … Read more